|
The Pharmacogenetics of Asthma Therapy (PhAT) project seeks to investigate genetic determinants of the variation in the treatment response to asthma. PharmGAT is funded as part of the National Institute of General Medical Sciences (NIGMS) and National Heart, Lung, and Blood Institutes (NHLBI) Pharmacogenetics Research Network and Knowledge Base (PGRN); the national repository for pharmacogenetics information generated by this network is known as the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). PharmGAT consists of investigators from the Brigham and Women’s Hospital, the University of Cincinnati, and the University of Colorado.
The long term objective of PharmGAT includes the ability to “individualize” therapy prospectively for subjects identified with asthma, allowing for optimal therapeutic effect while minimizing side effects. Additionally, since the pathophysiologic and therapeutic pathways of asthma overlap with many other diseases, the findings generated by this program may have much broad implications.
More Information
|
|